News

ivWatch Partners with National Infusion Center Association (NICA)

ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered.

In alignment, ivWatch and NICA are partnering with an emphasis on providing innovative and accessible solutions to freestanding infusion centers and their patients. The proprietary patient monitoring technology from ivWatch allows patients to have continuous IV site monitoring during infusions in the comfort and convenience of an outpatient setting.

“NICA has been the nation’s voice for independent infusion centers for more than a decade, overcoming countless barriers to care and access obstacles on behalf of patients and dedicated to ensuring that the nation’s infusion centers remain a safe, efficient, and cost-effective means of receiving consistent, high-quality care,” notes Brian Nyquist, MPH, NICA President and CEO. “We are excited to have ivWatch on board in 2024 as our trusted partner in helping our industry remain on the cutting edge of patient safety innovation.”

“Infusion centers are on the frontlines of IV patient safety, so this partnership is a natural fit,” says Erin Wendell, chief marketing officer at ivWatch. “It is also a perfect opportunity to work with this fast-growing segment of the healthcare industry in advocating for the increased adoption that a monitoring technology can play in reducing the severity of IV injuries while also mitigating the liability risks associated with IV extravasation and infiltration.”

This partnership comes at a monumental time of global adoption for ivWatch, as the company expands its reach to patients in all care areas that provide essential infusions. The company recently filed for 510(k) clearance for iron-based infusions to better protect patients not only from IV injuries but also the specific lifelong effects of irreversible skin staining that occurs with iron extravasations.

NICA and ivWatch will collaborate on several educational webinars relevant to infusion centers, including the recognition and interventions of early stages of IV extravasations to help promote safer delivery of IV therapy. The company will also exhibit at NICA’s annual conference on June 21-22, 2024, at the MGM Grand in Las Vegas in Booth 207. ivWatch will be a key participant at the exclusive NICA Infusion Center of Excellence (NICE) Experience, which provides an insider look at the ideal infusion center model. Products and technologies that improve patient care and promote patient safety will be displayed prominently. The event will provide a firsthand immersive experience for clinicians, administrators, managers, and owners.

 

Learn more here.

Recent News

11/04/2025

Op-Ed: Getting breakthrough coverage right: Rep. Griffith’s critical role

Virginia finds itself at the center of an important health care debate, and Southwest Virginia’s own U.S. Rep. Morgan Griffith, R-Salem, is in the driver’s seat as chair of the House Energy and Commerce Subcommittee on Health. Here’s the problem: Medicare beneficiaries can wait years — sometimes averaging half a decade — between when the

11/02/2025

AstraZeneca, Eli Lilly, Merck commit $120M to Virginia pharma training

Pharmaceutical giants AstraZeneca, Eli Lilly & Co. and Merck & Co. have committed a cumulative $120 million to develop a workforce training center for advanced pharmaceutical manufacturing in Central Virginia. The companies, each of which is planning to build manufacturing facilities in Virginia; the state government, including Virginia Innovation Partnership Corp.; and multiple Virginia colleges

10/27/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Last week, pharmaceutical giant Merck broke ground on a new $3 billion facility in Virginia that will create 8,000 construction jobs and 500 permanent manufacturing jobs. The new 400,000 square-foot, state-of-the-art plant isn’t merely the latest addition to Virginia’s rapidly growing biotech industry footprint. It’s a sign that America is making quick progress towards President